论文部分内容阅读
构建人肝癌组织特异性的基因治疗载体并探讨其临床意义。方法利用重组ＤＮＡ技术将ＨＳＶ－ＴＫ基因插入到含有及不含有α－ＦＰ启动子的ＥＢ病毒表达载体ＰＥＢＡＦ５．１、ｐＤＲ２中，并通过限制性内切酶分析鉴定重组质粒。结果ＴＫ基因成功地克隆入ＰＥＢＡＦ５．１及ｐＤＲ２中。结论含有α－ＦＰ启动子的ＥＢ病毒表达载体是原发性肝癌基因治疗中新型、理想的候选载体之一。
Construct a gene therapy vector specific for human hepatocellular carcinoma and discuss its clinical significance. Methods Recombinant DNA technology was used to insert the HSV-TK gene into the EB virus expression vector PEBAF5.1 and pDR2 with and without the α-FP promoter, and the recombinant plasmid was identified by restriction endonuclease analysis. Results The TK gene was successfully cloned into PEBAF5.1 and pDR2. Conclusion Epstein-Barr virus expression vector containing α-FP promoter is one of the new and ideal candidate vectors for gene therapy of primary liver cancer.